乐
乐观
乐观 · 25%KLRS
$2.74
情景价格
$2.420
+0.061 (+2.54%)收盘时
Loading chart…
- 最高
- 2.660
- 开盘
- 2.360
- 成交量加权均价
- 2.47
- 成交量
- 201.00K
- 市值
- —
- 最低
- 2.340
- 成交额
- 497.14K
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
AI 分析 of Kalaris Therapeutics Inc (KLRS)
持有Kalaris Therapeutics is currently not a strong buy due to its ongoing financial losses and low RSI of 45.617, indicating a lack of momentum. However, the stock has shown a recent 5-day increase of 11.11%, suggesting potential short-term recovery. The main risk is its negative earnings per share (EPS) of -0.46, which reflects ongoing profitability challenges.
估值指标
Kalaris Therapeutics Inc（KLRS）当前预期市盈率为 0.00，5 年平均预期市盈率为 -1.86。
Alphio AI 对 KLRS 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
持有 KLRS 的大户
事件时间线
资讯
7.008-04NewsfilterInvestigation into Kalaris Therapeutics Shareholder Claims
5.007-20seekingalphaKalaris Therapeutics Appoints New CFO
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in Retinal Diseases
9.007-17NASDAQ.COMKalaris Therapeutics Reports Positive Phase 1a Data for TH103 in AMD
- 2.007-17Newsfilter
Kalaris Reports Positive Data for TH103 in AMD Treatment
KLRS 常见问题 —— 由 Alphio AI 解答
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO). It operates in the Healthcare sector.
Kalaris Therapeutics is currently not a strong buy due to its ongoing financial losses and low RSI of 45.617, indicating a lack of momentum. However, the stock has shown a recent 5-day increase of 11.11%, suggesting potential short-term recovery. The main risk is its negative earnings per share (EPS) of -0.46, which reflects ongoing profitability challenges.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。